HealthEquity remains a 'buy' despite a 10.2% drop after 2027 guidance disappointed the market. HQY's core HSA business continues robust account and asset growth, driving consistent revenue and profit expansion. Management projects 2027 revenue of $1.38–$1.41 billion and EBITDA margins of 43.8–44.3%, supporting a bullish outlook.
Highlights of the third quarter include: Revenue increased 7% to $322.2 million. Net income per diluted share rose to $0.59 from $0.06 one year ago, and non-GAAP net income per diluted share increased 29% to $1.01.
HealthEquity, Inc. remains an asset-light growth opportunity, with a $120/share price target supported by strong Q2 FY26 results. HQY's recurring, asset-linked revenues, 70%+ gross margins, and expanding HSA penetration drive robust returns and positive operating leverage. Management's disciplined capital allocation, improving cost structure, and new legislative tailwinds expand HQY's total add...
DRAPER, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY), the nation's largest Health Savings Account (HSA) and consumer-directed benefits administrator, today announced a new development in building upon its technology investments to transform member experience. The company will deploy agentic AI capabilities that fundamentally change how members access support, working...
DRAPER, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- HealthEquity , Inc. (Nasdaq: HQY), the nation's largest Health Savings Accounts (HSAs) and consumer-directed benefits administrator, today announced two consumer-focused initiatives designed to expand access to affordable healthcare solutions for millions of American families: a curated platform connecting HealthEquity HSA members with affordable ...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.